Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2634 Target Snapshot

Tyrosine-protein kinase CSK · SINGLE PROTEIN · Homo sapiens

1,657Compounds
532Assays
18Approved Drugs
593.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt P41240. Use UniProt P41240 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P41240 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase CSK as ChEMBL target CHEMBL2634, mapped to UniProt P41240. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein kinase CSK
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2634
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P41240
Tyrosine-protein kinase CSK
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Tyrosine-protein kinase CSK is the right protein anchor across sources, using UniProt P41240 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTyrosine-protein kinase CSK
UniProt AccessionP41240
Component TypeProtein
Sequence Length450 aa

Tyrosine-protein kinase CSK

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Tyrosine-protein kinase CSK, mapped to UniProt P41240. Sequence length is 450 aa.

Mapped IDP41240
Review nameTyrosine-protein kinase CSK
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

18
Approved
4
Phase III
12
Phase II
6
Phase I
Assay Mix

Activity Type Distribution

IC50200.0
KI5.0
KD388.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5416410 9.0 Kd 1.0 Approved
CHEMBL5416410 8.89 IC50 1.3 Approved
CHEMBL591325 8.77 IC50 1.7 Preclinical
CHEMBL4582324 8.7 IC50 2.0 Preclinical
CHEMBL1873475 8.66 IC50 2.2 Approved
CHEMBL3647967 8.62 IC50 2.4 Preclinical
CHEMBL4443654 8.4 IC50 4.0 Preclinical
CHEMBL4445994 8.4 IC50 4.0 Preclinical
CHEMBL4537527 8.4 IC50 4.0 Preclinical
CHEMBL4545269 8.4 IC50 4.0 Preclinical
Distribution

pChEMBL Value Distribution

39
5.0
31
5.5
30
6.0
19
6.5
14
7.0
13
7.5
14
8.0
8
8.5
2
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

BRIGATINIB
CHEMBL3545311
Approved 2017
NERATINIB
CHEMBL180022
Approved 2017
IBRUTINIB
CHEMBL1873475
Approved 2013
DABRAFENIB
CHEMBL2028663
Approved 2013
PONATINIB
CHEMBL1171837
Approved 2012
BOSUTINIB
CHEMBL288441
Approved 2012
DASATINIB
CHEMBL5416410
Approved 2006
Assay Landscape

Assay Landscape

532
Total Assays
134
Tested Compounds
3
Assay Types
Binding — 528 assays, 134 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 409 111 6.5
cell-based format 44 7 5.7
assay format 40 2 7.1
subcellular format 35 14 6.4
Functional — 2 assays, 26 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 26 5.0
ADME — 2 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0
single protein format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine